Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

The prevalence and incidence rates of myasthenia gravis in the elderly US population have increased from 2006 to 2019.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell ...

1 "We welcome the FDA's decision to grant Priority Review for the treatment of generalized myasthenia gravis, which underscores the need for additional treatment options in a broad population of ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.